Articles By Jack Cush, MD
Adalimumab Effective in Pediatric Plaque Psoriasis
Adalimumab is currently FDA approved for use in adult psoriasis, pediatric Crohn's disease and polyarticular juvenile idiopathic arthritis. The current Lancet trial assesses the efficacy and safety of adalimumab in children and adolescents with severe plaque psoriasis.
Read Article
NSAIDs Increase Risk of Acute Myocardial Infarction
Using data from Canadian and European healthcare databases, the BMJ has reported that all NSAIDs, including celecoxib and naproxen, increase the risk of acute myocardial infarction.
Read Article
One-Third of FDA Approvals Need Post-Marketing Safety Changes
One-third of newly approved drugs in the next decade will require new safety warnings based on pharmacovigilance, according to a new study in JAMA. (Citation Source: http://buff.ly/2r3dYUs)
Read Article
Above-Label Dosing and Noncompliance with Biologics in Psoriatic Arthritis
Claims data analysis of 4245 psoriatic arthritis patients on TNF inhibitors showed both higher than expected durations of noncompliance and higher than label dosing - all at an increased cost.
Read Article
ACP Guideline Recommends Generic Bisphosphonates But Limits DEXA Use
The American College of Physicians (ACP) has updated its 2008 clincial practice guideline on the treatment of low bone density and osteoporosis to prevent fractures in men and women. The new guideline is in favor of generic bisphosphonate use and recommends against using menopausal estrogen therapy and against DEXA monitoring during the first 5 years.
Read Article
CDC Shows a 40% Lifetime Risk of Symptomatic Hand Osteoarthritis
Qin and colleagues have published in Arthritis & Rheumatology that 40% of people will be affected by symptomatic osteoarthritis in at least one hand. (Citation source: http://buff.ly/2qTUscZ)
Read Article
Increased Comorbidities in Rheumatoid Arthritis
A population based study from Taiwan examined the frequencies of comorbidities in a rheumatoid arthritis (RA) population.
Read Article
The RheumNow Week in Review – 5 May 2017
Dr Jack Cush reviews highlights from the news last week on RheumNow.com:
Read Article
US Drug Spending Will Rise Steadily Thru 2021
Reuters has reported that U.S.spending on prescription drugs in 2016 increased by 5.8 percent over 2015 levels to $450 billion based on list prices, and by 4.8 percent to $323 billion when adjusted for discounts and rebates.
Read Article
Tofacitinib Effective in Ulcerative Colitis
Tofacitinib is currently approved for use in rheumatoid arthritis, but is being studied in numerous other inflammatory conditons including spondylitis, psoriasis, and psoriatic arthritis, and has also been studied in patients with ulcerative colitis (UC).
Read Article
